IQVIA Biotech’s Post

Discover best practices to investigate novel blood cancer therapies with hematology experts Christopher Morley and Sari Heitner Enschede, MD. This insightful white paper explores how biotech companies can address the challenges around investigational agents for hematologic cancers, while considering patient diversity. https://bit.ly/3Aqv5Yw #hematology #oncology #diversity

A research study published in the journal 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴 reports the succesfull application of a p53 mRNA system for the therapy of high-grade serous ovarian carcinomas (OC), an aggressive cancer which exhibits high rates of tumor suppressor TP53 mutations.  https://lnkd.in/dYQdsbNJ #oncology #biomedicalresearch #medicine #lifescience #ovariancarninomas

Endpoints in malignant hematology studies differ significantly from those used for solid tumors. In this white paper, Christopher Morley and Sari Heitner Enschede, MD consider the most effective investigational agents for blood-based cancers. Download now. https://bit.ly/3KbJutp #oncology #hematology #biotech #ClinicalTrials #diversity

This month! Panome Bio proudly presents our webinar, "Integrated Multi-omics Analysis Reveals Systemic and Localized Metabolic Disruptions in Colorectal Cancer." A must-attend for anyone interested in the latest advancements in oncology research. Register now at the link below! Date: February 27, 2024 | Time: 12 PM Eastern Time Register Here: https://hubs.ly/Q02jWjqH0 #multiomics #metabolomics #proteomics #transcriptomics

Join Panome Bio, a fellow member of our thriving St. Louis biotech community, for their webinar: "Integrated Multi-omics Analysis Reveals Systemic and Localized Metabolic Disruptions in Colorectal Cancer" on Feb. 27. Register today for valuable insights and discussions. (see link below) #colorectalcancer #CRC #multiomics #metabolomics #proteomics #transcriptomics #stlmade #stlouis #biotechnology #stlmade

Structure elucidation of active compounds from Coffea canephora Pierre ex A.Froehner cascara and their potential as anticancer against breast cancer cells. https://ow.ly/FKmW50Qx2vq #BreastCancer #Phytochemistry #Pharmacology

Endpoints in malignant hematology studies differ significantly from those used for solid tumors. In this white paper, Christopher Morley and Sari Heitner Enschede, MD consider the most effective investigational agents for blood-based cancers. Download now. https://bit.ly/48xpIlR #oncology #hematology #biotech #ClinicalTrials #diversity

⏰ #SLAS2024 Session Starting: Join us at 12:00 PM EST, as Dr. Cathy Olsen explains how we used patient-derived colorectal cancer organoids to assess differential effects of known anti-cancer compounds on organoid size and morphology using both imaging and a microplate reader-based viability readout. This streamlined readout may be used to guide identification of potential therapeutics early in the screening process, which could then be followed up with more intensive high content imaging or other analyses. We hope to see you there! ➡️ https://bit.ly/3Unmca1   #CancerResearch #3DModels #CellViability #DrugDevelopment #HighContentScreening #TheFutureOfCellCulture #CellXpressAI

Structure elucidation of active compounds from Coffea canephora Pierre ex A.Froehner cascara and their potential as anticancer against breast cancer cells. https://ow.ly/1ZFM50Qx2vs #BreastCancer #Phytochemistry #Pharmacology

Structure elucidation of active compounds from Coffea canephora Pierre ex A.Froehner cascara and their potential as anticancer against breast cancer cells. https://ow.ly/8iGp50Qx2vr #BreastCancer #Phytochemistry #Pharmacology